ARI and global biopharmaceutical company AstraZeneca have partnered to provide an opportunity for researchers at the University of Adelaide to collaborate with industry-leading scientists to develop new medicines.
This partnership will allow for access to optimised compounds, technologies, multi-disciplinary science, services and know-how, with the prospect of joint publications in high profile journals and, most importantly, the opportunity to see ideas develop into treatments for patients.
Successful projects will be eligible for funding not only from AstraZeneca, but also from ARI’s Commercial Accelerator Scheme.
Concept proposals across ALL disease areas will be considered, however the five therapeutic areas that are more likely to be funded include:
- Cardiovascular & Metabolic Disease
- Oncology
- Respiratory/Inflammation
- Infection & Vaccines
- Neuroscience
You are invited to find out more by joining ARI and AstraZeneca representatives at the launch event:
When: 9:30am on 2 July 2015
Where: Ingkarni Wardli Level 7, Rm 715
RSVP at https://ariastrazeneca.eventbrite.com
Morning tea provided
Alternatively you can contact ARI on 8313 5020 and speak to your designated Commercial Development Manager